Latest results from IMPRESS (Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) 3 trial were presented at the Sexual Medicine Society of North America (SMSNA) 19th Annual Scientific Meeting in New Orleans, LA on November 21-24, 2013. According to the company press release:
Baseline patient characteristics:
- a mean penile curvature deformity of 53.0 degrees and a mean symptom bother score of 7.3.
- Endpoints of change in PCD and PD symptom bother were met with statistical significance compared to baseline.
- The mean percent change in penile curvature deformity was 34.4 percent and the mean change in PD symptom bother score was 3.3 from baseline.
- Clinical outcomes did not vary with prior PD treatment, erectile dysfunction scores and prostatectomy history.
- No significant difference in side effects between men with a curvature greater than or equal to 30 degrees versus lesser than 30 degrees.
I’m very enthusiastic about the upcoming FDA approval of this first non-surgical treatment for Peyronie’s disease that has demonstrated efficacy in randomized controlled trials.